{"Symbol": "ATOS", "AssetType": "Common Stock", "Name": "Atossa Genetics Inc", "Description": "Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.", "CIK": "1488039", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "107 SPRING STREET, SEATTLE, WA, UNITED STATES, 98104", "OfficialSite": "https://www.atossatherapeutics.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "36168000", "EBITDA": "-32840000", "PERatio": "None", "PEGRatio": "0", "BookValue": "5.78", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-3.45", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.299", "ReturnOnEquityTTM": "-0.489", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-3.45", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "68.75", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "3", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "0.723", "EVToRevenue": "-", "EVToEBITDA": "2.005", "Beta": "1.336", "52WeekHigh": "19.35", "52WeekLow": "3.76", "50DayMovingAverage": "9.17", "200DayMovingAverage": "11.9", "SharesOutstanding": "8611400", "SharesFloat": "8607400", "PercentInsiders": "0.329", "PercentInstitutions": "20.415", "DividendDate": "2018-04-20", "ExDividendDate": "None"}